SCHEMBL4039692

SCHEMBL4039692

COc1ccc(-c2cc(=O)c3ccc(OCCCCl)cc3o2)cc1

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.73
BCHE P06276 5/20 0.71
ACHE P22303 5/20 0.71
MEN1 O00255 2/20 0.65
TP53 P04637 2/20 0.65
CYP3A4 P08684 2/20 0.65
CYP2C9 P11712 2/20 0.65
CYP2C19 P33261 2/20 0.65
KMT2A Q03164 2/20 0.65
TNKS O95271 1/20 0.65
TNKS2 Q9H2K2 1/20 0.65
KDM4E B2RXH2 1/20 0.63
ALDH1A1 P00352 1/20 0.63
CYP2D6 P10635 1/20 0.63
MAPT P10636 1/20 0.63
HPGD P15428 1/20 0.63
HSD17B10 Q99714 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13797866 0.95 MAOB (0.73) MAOBBCHEACHEMEN1TP53
SCHEMBL13797869 0.90 MAOB (0.73) MAOBBCHEACHEMEN1TP53
SCHEMBL9388140 0.90 MAOB (0.68) MAOBBCHEACHE
SCHEMBL7372368 0.87 SIGMAR1 (0.72) TNKS
4,7-Dimethoxyflavone SCHEMBL3470601 0.85 MAOB (1.00) MAOBMEN1TP53CYP3A4CYP2C9
SCHEMBL9391105 0.82 SIGMAR1 (0.72) MEN1TP53CYP3A4KMT2ATNKS
SCHEMBL4036481 0.81 BCHE (0.90) BCHEACHE
SCHEMBL4403604 0.81 BCHE (0.62) MAOBBCHEACHEMEN1TP53
SCHEMBL7366672 0.80 SIGMAR1 (0.49) MAOBBCHEACHEKDM4EALDH1A1
SCHEMBL7656355 0.80 MAOB (0.83) MAOBMEN1TP53CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547794-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-06-16 US disclosed
EP-1615906-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES Vertex Pharmaceuticals Incorporated (US) 2006-01-18 EP disclosed
WO-2004092154-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-10-28 WO disclosed
US-20040198750-A1 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2004-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198750-A1 Compositions useful as inhibitors of protein kinases MAP3K20, MAP3K6, PACSIN2 MAOB 3049/4885BCHE 2627/4885ACHE 2871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.